Milestones

In the laboratories of SIRION BIOTECH this new technical option will be used for creating inducible cell and vector systems for the project business.

An important step was the signing of a sales agreement for Sirion products with the Japanese firm Cosmo Bio in January 2010, ensuring Sirion's expansion into the Asian market.

under which SIRION BIOTECH provides custom shRNA knockdown cell lines, utilizing validated The RNAi Consortium (TRC) shRNA RNAi libraries from Sigma Life Science. First of all the offer is limited to the German research community.

By identifying the antigen profiles in the natural in vivo milieu of infectious bacteria the alliance will develop new diagnostic and immunization strategies. Part of the project is also to develop more sophisticated T-Zell analysis for improved epitope maps of viral deseases.

The test customers detected up to 50 fold enhanced expression rates depending on the cell type. In addition, TransMAX has been shown to now enable gene transfer to human dendritic cells, mouse embryonic stem cell or skeletal muscle cells having a wide impact on the corresponding scientific areas.

The funding will help SIRION BIOTECH to enhance their activities in foreign markets and to accelerate the speed of developing products in the area of adenovirus vector technology.

In the two years cooperation project funded with approx. 300 tEUR SIRION BIOTECH will facilitate viral delivery of siRNAs to hematopoietic cells which HGMU will use for target validation in leukemia research.

After having received a High Tech Gründerfond (HTGF) financing in 2007 the company has approved the market acceptance of their services and products in the sector of genetically modified cells and vector systems. The new financing round with Clusterfond Start up! being in the lead investor is intended for accelerating the pace of the market entry.

SIRION GmbH, a supplier of tools & services for RNAi-based functional gene analysis, raised an early-stage funding from High-Tech-Gründerfonds, Bayernkapital and Creathor Venture.

Press release

SIRION started in new laboratories in IZB in Martinsried its service and product business in providing gene function tools.

SIRION GmbH was one of the winners of the
Science4life business plan competition.

SIRION GmbH filed patent for its proprietary Q-tech technology.

SIRION GmbH signed license agreement for storage and shipment technology with CCS GmbH, Hamburg.

SIRION GmbH was founded in Munich as a biotech company for innovative services and products for gene silencing and customized gene expression solutions.